---
schema_version: "secwatch.filing_event.v1"
accession: "0001178913-26-003966"
form_type: "8-K"
ticker: "SLXN"
cik: "0002022416"
company_name: "Silexion Therapeutics Corp"
filed_at: "2026-08-10T10:16:08+00:00"
generated_at: "2026-08-10T10:20:10.595911+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Silexion starts SIL204 Phase 2/3 in pancreatic cancer; FDA pre-IND expected Q1 2027

## Summary
- Phase 2/3 safety run-in for SIL204 in LAPC initiated July 2026; approved by Israel MoH and Germany BfArM.
- Early human data expected Q4 2026; IND application and US/EU expansion planned Q1 2027.
- SIL204 targets >74% of KRAS mutations in PDAC; sub-nanomolar IC50 across G12D/V/C/R and others.
- Preclinical data show tumor growth inhibition, synergy with FOLFIRI, and 11-fold safety margins.
- Toxicology package for marketing approval planned H2 2026; collaboration with Catalent and Axolabs for GMP supply.

## SEC filing metadata
- accession: 0001178913-26-003966
- form_type: 8-K
- ticker: SLXN
- cik: 0002022416
- company_name: Silexion Therapeutics Corp
- filed_at: 2026-08-10T10:16:08+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003966/0001178913-26-003966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2022416/000117891326003966/zk2635901.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001178913-26-003966
- JSON: https://secwatch.observer/filing/0001178913-26-003966.json
- Plain text: https://secwatch.observer/filing/0001178913-26-003966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.